Kellen Rolling, NP
Family · Vestavia Hills, ALNPI 1821310095
Payments from drug & device makers
Across 792 payments — averaging $14.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- AbbVie$2K
- Lilly USA, LLC$1K
- Amgen$738
- Takeda Pharmaceuticals U.S.A., Inc.$649
- Pfizer$355
- plus $3K from 32 others
What the payments were for
- Food & beverage$11,17299%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 219 | $2,835 |
| AbbVie | 203 | $2,236 |
| Lilly USA, LLC | 90 | $1,296 |
| Amgen | 45 | $738 |
| Takeda Pharmaceuticals U.S.A., Inc. | 35 | $649 |
| Pfizer | 23 | $355 |
| Biohaven Pharmaceutical Holding Company Ltd. | 16 | $279 |
| Boehringer Ingelheim | 16 | $252 |
| IBSA Pharma Inc. | 13 | $229 |
| Amarin Pharma, Inc. | 13 | $200 |
| Dexcom, Inc. | 11 | $193 |
| Exact Sciences | 14 | $192 |
| AstraZeneca | 6 | $187 |
| Eisai Inc. | 15 | $143 |
| Biohaven Pharmaceuticals, Inc. | 7 | $136 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $133 |
| Silk Road Medical, Inc. | 1 | $123 |
| Shield Therapeutics Inc | 7 | $114 |
| Astellas Pharma US Inc | 1 | $100 |
| Merck | 6 | $99 |
| Axsome Therapeutics, Inc. | 5 | $95 |
| Boston Scientific | 1 | $92 |
| Bayer | 5 | $88 |
| GSK | 5 | $87 |
| Sanofi-aventis U.S. LLC | 4 | $58 |
| Corcept Therapeutics | 3 | $56 |
| Teva Pharmaceuticals USA, Inc. | 2 | $44 |
| Kowa Pharmaceuticals America, Inc. | 3 | $42 |
| Johnson & Johnson | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Novartis | 1 | $26 |
| Sumitomo Pharma America, Inc. | 2 | $26 |
| Bausch Health US, LLC | 2 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Genentech USA, Inc. | 2 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Saxenda$247
- Wegovy$225
- ENROUTE Transcarotid Stent$123
- ENROUTE Transcarotid Neuroprotection System$123
- MOUNJARO$122
- FASENRA$116
- Ozempic$104
How this compares
$11,272 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $105,085 |
| MounjaroTirzepatide | 38 | $43,321 |
| LinzessLinaclotide | 20 | $21,555 |
| JardianceEmpagliflozin | 14 | $19,527 |
| MyrbetriqMirabegron | 16 | $10,499 |
| EliquisApixaban | 11 | $10,084 |
| Repatha SureclickEvolocumab | 11 | $5,977 |
| MovantikNaloxegol Oxalate | 12 | $4,671 |
| Atorvastatin Calcium | 219 | $3,405 |
| Levothyroxine Sodium | 181 | $2,511 |
| SynthroidLevothyroxine Sodium | 25 | $2,462 |
| Losartan Potassium | 130 | $1,604 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,433 |
| Famotidine | 68 | $1,330 |
| Fenofibrate | 53 | $1,290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,835 | $105,08575 claims |
| Lilly USA, LLCMounjaro | $1,296 | $43,32138 claims |
| AbbVieLinzess, Synthroid | $2,236 | $24,01745 claims |
| Boehringer IngelheimJardiance | $252 | $19,52714 claims |
| Astellas Pharma US IncMyrbetriq | $100 | $10,49916 claims |
| PfizerEliquis | $355 | $10,08411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.
Other family in Vestavia Hills
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.